SlideShare a Scribd company logo
Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter Singh, B, MD; Connolly, S, MD; Crijns, H, MD; Roy, D, MD; Kowey, P, MD; Capucci, A., MD; Radzig, D., MD; Aliot, E, MD for the Euridis and Adonis Investigators. NEJM,  September 6, 2007  Linda Nabha, MD October 23, 2007
Atrial Fibrillation ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment Strategies for AF  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Amiodarone ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Dronedarone ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Study Hypothesis ,[object Object],[object Object]
Selection of Subjects ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Exclusion Criteria ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Study Design ,[object Object],[object Object],[object Object],[object Object]
Baseline Evaluation, Randomization, Therapy ,[object Object],[object Object],[object Object],[object Object],[object Object]
Follow up ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Study End Points ,[object Object],[object Object],[object Object],[object Object],[object Object]
Statistical Analysis ,[object Object],[object Object],[object Object]
Enrollment and Outcomes
Enrollment and Outcomes
Baseline Characteristics European Placebo  Dronedarone Non-European Placebo  Dronedarone Combined Placebo  Dronedarone Age (yr) 61.3 62.3 63 64.6 62.2 63.5 Sex (%F) 30.3 30.7 32.7 29.7 31.5 30.2 Structural HD 33.3 36.3 45.6 48.5 39.7 42.4 LVEF % 59.83 + 9.37 59.6 + 10 57.1 + 12.2 57.9 + 11.2 58.5 + 11 58.6 + 1.8 Recent cardio-version* % 37.3 37.2 22.1 21.6 29.6 29.3
Results ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Results
Results ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Results
Adverse Events VARIABLE DRONEDARONE N=828 PLACEBO N=409 P value Stroke 4 (0.5) 3 (0.7) 0.69 Cough Dyspnea 19 (2.3) 7(1.7) 0.67 Hyperthyroidism Hypothyroidism 67/801 (8.4) 44/801 (5.5 56/396 (14.1) 14/396 (3.5) 0.002 0.15 Abnormal LFTs 100/822 (12.2) 55/404(13.6) 0.52 Elev of  Serum Creatinine 20 (2.4) 1 (0.2) 0.004 Bradycardia Heart Failure 22 (2.7) 20 (2.4) 8 (2.2) 4 (1.0) 0.56 0.12
Limitations ,[object Object],[object Object],[object Object],[object Object]
Discussion ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Applications to Clinical Practice ,[object Object],[object Object],[object Object]
QUESTIONS?

More Related Content

What's hot

New Treatments in HFrEF
New Treatments in HFrEFNew Treatments in HFrEF
New Treatments in HFrEF
Duke Heart
 
Carvedilol in the management of mi and heart failure
Carvedilol  in the management of mi and heart failureCarvedilol  in the management of mi and heart failure
Carvedilol in the management of mi and heart failure
Dr.Pankaj Jariwala
 
Strategy to Go for Goal in Dyslipidemia with Acute Coronary Syndrome Patients
Strategy to Go for Goal in Dyslipidemia with Acute Coronary Syndrome PatientsStrategy to Go for Goal in Dyslipidemia with Acute Coronary Syndrome Patients
Strategy to Go for Goal in Dyslipidemia with Acute Coronary Syndrome Patients
PERKI Pekanbaru
 
Evidence-based management of CHF
Evidence-based management of CHFEvidence-based management of CHF
Evidence-based management of CHF
MedPeds Hospitalist
 
In case bleeding due to anticoagulan, what should we do?
In case bleeding due to anticoagulan, what should we do?In case bleeding due to anticoagulan, what should we do?
In case bleeding due to anticoagulan, what should we do?
Faris Basalamah, MD FIHA
 
Management strategy in HF with ARNI - Recent updates
Management strategy in HF with ARNI - Recent updates Management strategy in HF with ARNI - Recent updates
Management strategy in HF with ARNI - Recent updates
Praveen Nagula
 
Dual Therapy with Aspirin and Rivaroxaban -Dr. Verhamme
Dual Therapy with Aspirin and Rivaroxaban -Dr. VerhammeDual Therapy with Aspirin and Rivaroxaban -Dr. Verhamme
Dual Therapy with Aspirin and Rivaroxaban -Dr. Verhamme
Sociedad Española de Cardiología
 
AHA: EMPHASIS-HF Trial
AHA: EMPHASIS-HF TrialAHA: EMPHASIS-HF Trial
AHA: EMPHASIS-HF Trial
TriMed Media Group
 
Atrial fibrillation and anticoagulants
Atrial fibrillation and anticoagulantsAtrial fibrillation and anticoagulants
Atrial fibrillation and anticoagulantsshahhcnt
 
Acute Heart Failure – The road to where
Acute Heart Failure – The road to whereAcute Heart Failure – The road to where
Acute Heart Failure – The road to where
drucsamal
 
Sacubitril valsartan EK
Sacubitril valsartan EKSacubitril valsartan EK
Sacubitril valsartan EK
Edgardo Kaplinsky
 
Serelaxin in acute heart failure
Serelaxin in acute heart failureSerelaxin in acute heart failure
Serelaxin in acute heart failure
drucsamal
 
Serelaxin.
Serelaxin.Serelaxin.
Serelaxin.
Mukesh Mishra
 
Channalging Cases in AHF Hypoperfusion
Channalging Cases in AHF HypoperfusionChannalging Cases in AHF Hypoperfusion
Channalging Cases in AHF Hypoperfusion
drucsamal
 

What's hot (14)

New Treatments in HFrEF
New Treatments in HFrEFNew Treatments in HFrEF
New Treatments in HFrEF
 
Carvedilol in the management of mi and heart failure
Carvedilol  in the management of mi and heart failureCarvedilol  in the management of mi and heart failure
Carvedilol in the management of mi and heart failure
 
Strategy to Go for Goal in Dyslipidemia with Acute Coronary Syndrome Patients
Strategy to Go for Goal in Dyslipidemia with Acute Coronary Syndrome PatientsStrategy to Go for Goal in Dyslipidemia with Acute Coronary Syndrome Patients
Strategy to Go for Goal in Dyslipidemia with Acute Coronary Syndrome Patients
 
Evidence-based management of CHF
Evidence-based management of CHFEvidence-based management of CHF
Evidence-based management of CHF
 
In case bleeding due to anticoagulan, what should we do?
In case bleeding due to anticoagulan, what should we do?In case bleeding due to anticoagulan, what should we do?
In case bleeding due to anticoagulan, what should we do?
 
Management strategy in HF with ARNI - Recent updates
Management strategy in HF with ARNI - Recent updates Management strategy in HF with ARNI - Recent updates
Management strategy in HF with ARNI - Recent updates
 
Dual Therapy with Aspirin and Rivaroxaban -Dr. Verhamme
Dual Therapy with Aspirin and Rivaroxaban -Dr. VerhammeDual Therapy with Aspirin and Rivaroxaban -Dr. Verhamme
Dual Therapy with Aspirin and Rivaroxaban -Dr. Verhamme
 
AHA: EMPHASIS-HF Trial
AHA: EMPHASIS-HF TrialAHA: EMPHASIS-HF Trial
AHA: EMPHASIS-HF Trial
 
Atrial fibrillation and anticoagulants
Atrial fibrillation and anticoagulantsAtrial fibrillation and anticoagulants
Atrial fibrillation and anticoagulants
 
Acute Heart Failure – The road to where
Acute Heart Failure – The road to whereAcute Heart Failure – The road to where
Acute Heart Failure – The road to where
 
Sacubitril valsartan EK
Sacubitril valsartan EKSacubitril valsartan EK
Sacubitril valsartan EK
 
Serelaxin in acute heart failure
Serelaxin in acute heart failureSerelaxin in acute heart failure
Serelaxin in acute heart failure
 
Serelaxin.
Serelaxin.Serelaxin.
Serelaxin.
 
Channalging Cases in AHF Hypoperfusion
Channalging Cases in AHF HypoperfusionChannalging Cases in AHF Hypoperfusion
Channalging Cases in AHF Hypoperfusion
 

Viewers also liked

Ijc102307(nabha)
Ijc102307(nabha)Ijc102307(nabha)
Ijc102307(nabha)
Daniele Caraceni
 
Shift kol 01
Shift    kol 01Shift    kol 01
Shift kol 01
Daniele Caraceni
 
Henrik von Wehrs - Rechtliche Einschätzung und Bewertung der Echtzeitkommunik...
Henrik von Wehrs - Rechtliche Einschätzung und Bewertung der Echtzeitkommunik...Henrik von Wehrs - Rechtliche Einschätzung und Bewertung der Echtzeitkommunik...
Henrik von Wehrs - Rechtliche Einschätzung und Bewertung der Echtzeitkommunik...
Michael Gebert
 
Thecrowd
ThecrowdThecrowd
Thecrowd
bflood
 
تقويم برنامج
تقويم برنامجتقويم برنامج
تقويم برنامج
u061423
 
InterCommIT Factuurcongres 2010 Managed eInvoicing Parallelsessie
InterCommIT Factuurcongres 2010 Managed eInvoicing ParallelsessieInterCommIT Factuurcongres 2010 Managed eInvoicing Parallelsessie
InterCommIT Factuurcongres 2010 Managed eInvoicing ParallelsessieFactuurcongres
 
Athena
AthenaAthena

Viewers also liked (8)

Ijc102307(nabha)
Ijc102307(nabha)Ijc102307(nabha)
Ijc102307(nabha)
 
Shift kol 01
Shift    kol 01Shift    kol 01
Shift kol 01
 
Henrik von Wehrs - Rechtliche Einschätzung und Bewertung der Echtzeitkommunik...
Henrik von Wehrs - Rechtliche Einschätzung und Bewertung der Echtzeitkommunik...Henrik von Wehrs - Rechtliche Einschätzung und Bewertung der Echtzeitkommunik...
Henrik von Wehrs - Rechtliche Einschätzung und Bewertung der Echtzeitkommunik...
 
Safety
SafetySafety
Safety
 
Thecrowd
ThecrowdThecrowd
Thecrowd
 
تقويم برنامج
تقويم برنامجتقويم برنامج
تقويم برنامج
 
InterCommIT Factuurcongres 2010 Managed eInvoicing Parallelsessie
InterCommIT Factuurcongres 2010 Managed eInvoicing ParallelsessieInterCommIT Factuurcongres 2010 Managed eInvoicing Parallelsessie
InterCommIT Factuurcongres 2010 Managed eInvoicing Parallelsessie
 
Athena
AthenaAthena
Athena
 

Similar to Ijc102307(nabha)

Acute Heart Failure
Acute Heart FailureAcute Heart Failure
Acute Heart Failure
Edgar Hernández
 
Cardiac Resynchronisation Therapy
Cardiac Resynchronisation TherapyCardiac Resynchronisation Therapy
Cardiac Resynchronisation Therapycardiologycases
 
Cardiac Resynchronisation Therapy
Cardiac Resynchronisation TherapyCardiac Resynchronisation Therapy
Cardiac Resynchronisation Therapycardiologycases
 
Cardiac Resynchronisation Therapy
Cardiac  Resynchronisation  TherapyCardiac  Resynchronisation  Therapy
Cardiac Resynchronisation Therapycardiologycases
 
Cardiac Resynchronisation Therapy
Cardiac Resynchronisation TherapyCardiac Resynchronisation Therapy
Cardiac Resynchronisation Therapycardiologycases
 
Cardiac Resynchronisation Therapy
Cardiac Resynchronisation TherapyCardiac Resynchronisation Therapy
Cardiac Resynchronisation Therapycardiologycases
 
BCC4: Delaney on Stats and Trials "Stuff"
BCC4: Delaney on Stats and Trials "Stuff"BCC4: Delaney on Stats and Trials "Stuff"
BCC4: Delaney on Stats and Trials "Stuff"
SMACC Conference
 
Syncope
Syncope  Syncope
Syncope
SMSRAZA
 
Syncope
Syncope  Syncope
Syncope SMSRAZA
 
Update on Pulmonary Arterial Hypertension in Scleroderma
Update on Pulmonary Arterial Hypertension in SclerodermaUpdate on Pulmonary Arterial Hypertension in Scleroderma
Update on Pulmonary Arterial Hypertension in Scleroderma
Scleroderma Foundation of Greater Chicago
 
Van Gelder Race
Van Gelder RaceVan Gelder Race
Van Gelder Raceenforme
 
Heart failure api
Heart failure apiHeart failure api
Heart failure api
drucsamal
 
TAEM10: How To Help Copd Patients Feel Better And
TAEM10: How To Help Copd Patients Feel Better AndTAEM10: How To Help Copd Patients Feel Better And
TAEM10: How To Help Copd Patients Feel Better And
taem
 
Breaking the-cardiovascular-disease-continuum
Breaking the-cardiovascular-disease-continuumBreaking the-cardiovascular-disease-continuum
Breaking the-cardiovascular-disease-continuum
KadarabadNarsingarao
 
Ohio State's 2016 ASH Review - BEST OF ASH 2015 MULTIPLE MYELOMA AND PLASMA C...
Ohio State's 2016 ASH Review - BEST OF ASH 2015 MULTIPLE MYELOMA AND PLASMA C...Ohio State's 2016 ASH Review - BEST OF ASH 2015 MULTIPLE MYELOMA AND PLASMA C...
Ohio State's 2016 ASH Review - BEST OF ASH 2015 MULTIPLE MYELOMA AND PLASMA C...
OSUCCC - James
 
Primary Hyperadosteronism
Primary HyperadosteronismPrimary Hyperadosteronism
Primary HyperadosteronismJoel Topf
 
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease BurdenVenous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
NBCA
 
Bd1e Management Of Heart Failure
Bd1e Management Of Heart FailureBd1e Management Of Heart Failure
Bd1e Management Of Heart Failuremario valenza
 
Acute Decompensated Heart Failure
Acute Decompensated Heart FailureAcute Decompensated Heart Failure
Acute Decompensated Heart Failure
drucsamal
 

Similar to Ijc102307(nabha) (20)

Acute Heart Failure
Acute Heart FailureAcute Heart Failure
Acute Heart Failure
 
Cardiac Resynchronisation Therapy
Cardiac Resynchronisation TherapyCardiac Resynchronisation Therapy
Cardiac Resynchronisation Therapy
 
Cardiac Resynchronisation Therapy
Cardiac Resynchronisation TherapyCardiac Resynchronisation Therapy
Cardiac Resynchronisation Therapy
 
Cardiac Resynchronisation Therapy
Cardiac  Resynchronisation  TherapyCardiac  Resynchronisation  Therapy
Cardiac Resynchronisation Therapy
 
Cardiac Resynchronisation Therapy
Cardiac Resynchronisation TherapyCardiac Resynchronisation Therapy
Cardiac Resynchronisation Therapy
 
Cardiac Resynchronisation Therapy
Cardiac Resynchronisation TherapyCardiac Resynchronisation Therapy
Cardiac Resynchronisation Therapy
 
BCC4: Delaney on Stats and Trials "Stuff"
BCC4: Delaney on Stats and Trials "Stuff"BCC4: Delaney on Stats and Trials "Stuff"
BCC4: Delaney on Stats and Trials "Stuff"
 
Syncope
Syncope  Syncope
Syncope
 
Syncope
Syncope  Syncope
Syncope
 
Update on Pulmonary Arterial Hypertension in Scleroderma
Update on Pulmonary Arterial Hypertension in SclerodermaUpdate on Pulmonary Arterial Hypertension in Scleroderma
Update on Pulmonary Arterial Hypertension in Scleroderma
 
Van Gelder Race
Van Gelder RaceVan Gelder Race
Van Gelder Race
 
Heart failure api
Heart failure apiHeart failure api
Heart failure api
 
TAEM10: How To Help Copd Patients Feel Better And
TAEM10: How To Help Copd Patients Feel Better AndTAEM10: How To Help Copd Patients Feel Better And
TAEM10: How To Help Copd Patients Feel Better And
 
Breaking the-cardiovascular-disease-continuum
Breaking the-cardiovascular-disease-continuumBreaking the-cardiovascular-disease-continuum
Breaking the-cardiovascular-disease-continuum
 
Ohio State's 2016 ASH Review - BEST OF ASH 2015 MULTIPLE MYELOMA AND PLASMA C...
Ohio State's 2016 ASH Review - BEST OF ASH 2015 MULTIPLE MYELOMA AND PLASMA C...Ohio State's 2016 ASH Review - BEST OF ASH 2015 MULTIPLE MYELOMA AND PLASMA C...
Ohio State's 2016 ASH Review - BEST OF ASH 2015 MULTIPLE MYELOMA AND PLASMA C...
 
Primary Hyperadosteronism
Primary HyperadosteronismPrimary Hyperadosteronism
Primary Hyperadosteronism
 
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease BurdenVenous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
 
Bd1e Management Of Heart Failure
Bd1e Management Of Heart FailureBd1e Management Of Heart Failure
Bd1e Management Of Heart Failure
 
Lancelot acs final
Lancelot acs finalLancelot acs final
Lancelot acs final
 
Acute Decompensated Heart Failure
Acute Decompensated Heart FailureAcute Decompensated Heart Failure
Acute Decompensated Heart Failure
 

Recently uploaded

The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
MedicoseAcademics
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
Dr. Jyothirmai Paindla
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
NephroTube - Dr.Gawad
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAdv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
AkankshaAshtankar
 
Gram Stain introduction, principle, Procedure
Gram Stain introduction, principle, ProcedureGram Stain introduction, principle, Procedure
Gram Stain introduction, principle, Procedure
Suraj Goswami
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Dr. Madduru Muni Haritha
 
Colonic and anorectal physiology with surgical implications
Colonic and anorectal physiology with surgical implicationsColonic and anorectal physiology with surgical implications
Colonic and anorectal physiology with surgical implications
Dr Maria Tamanna
 
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley LifesciencesPharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Yodley Lifesciences
 
CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}
NEHA GUPTA
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Sex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skullSex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skull
ShashankRoodkee
 
Top-Vitamin-Supplement-Brands-in-India.pptx
Top-Vitamin-Supplement-Brands-in-India.pptxTop-Vitamin-Supplement-Brands-in-India.pptx
Top-Vitamin-Supplement-Brands-in-India.pptx
SwisschemDerma
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 

Recently uploaded (20)

The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAdv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
 
Gram Stain introduction, principle, Procedure
Gram Stain introduction, principle, ProcedureGram Stain introduction, principle, Procedure
Gram Stain introduction, principle, Procedure
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
 
Colonic and anorectal physiology with surgical implications
Colonic and anorectal physiology with surgical implicationsColonic and anorectal physiology with surgical implications
Colonic and anorectal physiology with surgical implications
 
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley LifesciencesPharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
 
CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
 
Sex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skullSex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skull
 
Top-Vitamin-Supplement-Brands-in-India.pptx
Top-Vitamin-Supplement-Brands-in-India.pptxTop-Vitamin-Supplement-Brands-in-India.pptx
Top-Vitamin-Supplement-Brands-in-India.pptx
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 

Ijc102307(nabha)

  • 1. Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter Singh, B, MD; Connolly, S, MD; Crijns, H, MD; Roy, D, MD; Kowey, P, MD; Capucci, A., MD; Radzig, D., MD; Aliot, E, MD for the Euridis and Adonis Investigators. NEJM, September 6, 2007 Linda Nabha, MD October 23, 2007
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 16. Baseline Characteristics European Placebo Dronedarone Non-European Placebo Dronedarone Combined Placebo Dronedarone Age (yr) 61.3 62.3 63 64.6 62.2 63.5 Sex (%F) 30.3 30.7 32.7 29.7 31.5 30.2 Structural HD 33.3 36.3 45.6 48.5 39.7 42.4 LVEF % 59.83 + 9.37 59.6 + 10 57.1 + 12.2 57.9 + 11.2 58.5 + 11 58.6 + 1.8 Recent cardio-version* % 37.3 37.2 22.1 21.6 29.6 29.3
  • 17.
  • 19.
  • 21. Adverse Events VARIABLE DRONEDARONE N=828 PLACEBO N=409 P value Stroke 4 (0.5) 3 (0.7) 0.69 Cough Dyspnea 19 (2.3) 7(1.7) 0.67 Hyperthyroidism Hypothyroidism 67/801 (8.4) 44/801 (5.5 56/396 (14.1) 14/396 (3.5) 0.002 0.15 Abnormal LFTs 100/822 (12.2) 55/404(13.6) 0.52 Elev of Serum Creatinine 20 (2.4) 1 (0.2) 0.004 Bradycardia Heart Failure 22 (2.7) 20 (2.4) 8 (2.2) 4 (1.0) 0.56 0.12
  • 22.
  • 23.
  • 24.

Editor's Notes

  1. Approximately 2.5 million Americans, or close to 1% of the total population, currently have atrial fibrillation lack of coordinated atrial contraction leads to unusual fluid flow states through the atrium that are permissive for formation of thrombus that is then at risk to embolize
  2. There are two standard approaches to converting AF to sinus rhythm: synchronized external DC cardioversion and pharmacologic cardioversion. Anticoagulation should be achieved with adjusted-dose warfarin unless the patient is considered at low embolic risk or has a contraindication.
  3. Amiodarone has multiple effects on myocardial depolarization and repolarization that make it an extremely effective antiarrhythmic drug. pulmonary toxicity usually occurs several months to as late as several years after the initiation Thyroid dysfunction (including both hypothyroidism and hyperthyroidism
  4. The iodine moiety has been thought involved in amiodarone 's pulmonary toxicity, hepatitis, thyroid side effects, and eye disturbances. Thus, dronedarone may have fewer of the long-term complications associated with amiodarone. In the ANDROMEDA trial, pt were high risk pt with severe CHF and ventricular dysfunction
  5. Interesting to note here, sinus rhythm was achieved in these participants in multiple ways: Including cardioversion up to one hour prior to randomization and Previous treatment of with amiodaone was permitted and pt who had received the drug could be enrolled immediately after its discontinuation.
  6. Class I includes:Digoxin, quinidine Class III includes
  7. The hypothesis for determining the number of pt needed for the study was based on efficacy trials comparing amiodarone to placebo and the presumption that 60% of pt in the placebo group would have a recurrence of an arrythmia and those in the dronedarone group would a a decreased in this rate of at least 25%
  8. Each trial would have a power of 90% to detect a between group difference .
  9. This was defined as an episode lasting for at least 10 minutes and confirmed by 2 consecutive recordings taken 10 min apart on a 12 lead EKG or transtelephonic monitoring. Symptoms included dyspnea, chest pain, fatigue, dizziness
  10. With all randomized patients who received at least one dose of a study drug included
  11. Recent cardioversion included within last 5 days of randomization
  12. This information is seen in chart form: On the verticle axis is the variables Horizontally are the trials. Median Days to recurrence Recurrence rate at 12 months
  13. Again on verticle axis are the variables On the horizontal axis is the trials
  14. This is a modified chart of the adverse side effects and lab values. Singh et al excluded pt who inconsistent changes in measeures of thyroid function. Pt with no abnormalityh and with at least one missing measurement of liver function were exluded
  15. 1. Since the study didn’t directly compare the drugs there is no certainty that dronedarone is as efficacious as amiodarone or that the adverse events is lower. 2. The majority of AF in general fibrillation may be symptomatic. It is likely they were not able to detect all or the first episode of Afib in a patient Since the primary endpoint was to detect the occurrence of the endpoint. 3. One of the major side effects of amio is the pulmonary toxicity which occurs years into taking amio. Most patients did not have CXR done during the study unless pt had pulmonary symptoms.